Danyang Li

Danyang Li

Auto-generated profile, based on publicly available information

Danyang Li

Social, Genetic, and Developmental Psychiatry Centre; Institute of Psychiatry, Psychology and Neuroscience; King's College London, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WWWin Lee Edwin Wong
Win Lee Edwin Wong
CFChiara Fabbri
Chiara Fabbri
BLBenjamin Laplace
Benjamin Laplace
DLDanyang Li
Danyang Li
Roos van WestrhenenRoos van Westrhenen
Roos van Westrhenen
Allan YoungAllan Young
Allan Young
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly. CYP2C19 is a key enzyme involved in the metabolism of several drugs, including SSRIs. Variations in the CYP2C19 gene are associated with differential metabolic activity, and thus differential SSRI exposure; accordingly, the CYP2C19 genotype may affect the therapeutic response and clinical outcomes, though existing evidence of this link is not entirely consistent. Therefore, we analysed data from the UK Biobank, a large, deeply phenotyped prospective study, to investigate the effects of CYP2C19 metaboliser phenotypes on several clinical outcomes derived from primary care records, including multiple measures of antidepressant switching, discontinuation, duration, and side effects. In this dataset, 24,729 individuals were prescribed citalopram, 3012 individuals were prescribed escitalopram, and 12,544 individuals were prescribed sertraline. Consistent with pharmacological expectations, CYP2C19 poor metabolisers on escitalopram were more likely to switch antidepressants, have side effects following first prescription, and be on escitalopram for a shorter duration compared to normal metabolisers. CYP2C19 poor and intermediate metabolisers on citalopram also exhibited increased odds of discontinuation and shorter durations relative to normal metabolisers. Generally, no associations were found between metabolic phenotypes and proxies of response to sertraline. Sensitivity analyses in a depression subgroup and metabolic activity scores corroborated results from the primary analysis. In summary, our findings suggest that CYP2C19 genotypes, and thus metabolic phenotypes, may have utility in determining clinical responses to SSRIs, particularly escitalopram and citalopram, though further investigation of such a relationship is warranted.

19 July 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
DLDanyang Li
Danyang Li
OPOliver Pain
Oliver Pain
CFChiara Fabbri
Chiara Fabbri
WWWin Lee Edwin Wong
Win Lee Edwin Wong
CLChris Wai Hang Lo
Chris Wai Hang Lo
CLCathryn Lewis
Cathryn Lewis
Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.

10 October 2023 in Biology Open
Verified
Journal Article
Open access
PDF file
FMFrancesca Mastropasqua
Francesca Mastropasqua
MOMarika Oksanen
Marika Oksanen
CSCristina Soldini
Cristina Soldini
SAShemim Alatar
Shemim Alatar
AAAbishek Arora
Abishek Arora
KTKristiina Tammimies
Kristiina Tammimies
Genetic variants affecting Heterogeneous Nuclear Ribonucleoprotein U (HNRNPU) have been identified in several neurodevelopmental disorders (NDDs). HNRNPU is widely expressed in the human brain and shows the highest postnatal expression in the cerebellum. Recent studies have investigated the role of HNRNPU in cerebral cortical development, but the effects of HNRNPU deficiency on cerebellar development remain unknown. Here, we describe the molecular and cellular outcomes of HNRNPU locus deficiency during in vitro neural differentiation of patient-derived and isogenic neuroepithelial stem cells with a hindbrain profile. We demonstrate that HNRNPU deficiency leads to chromatin remodeling of A/B compartments, and transcriptional rewiring, partly by impacting exon inclusion during mRNA processing. Genomic regions affected by the chromatin restructuring and host genes of exon usage differences show a strong enrichment for genes implicated in epilepsies, intellectual disability, and autism. Lastly, we show that at the cellular level HNRNPU downregulation leads to an increased fraction of neural progenitors in the maturing neuronal population. We conclude that the HNRNPU locus is involved in delayed commitment of neural progenitors to differentiate in cell types with hindbrain profile.

28 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KDKatrina A.S. Davis
Katrina A.S. Davis
Jonathan ColemanJonathan Coleman
Jonathan Coleman
MAMark Adams
Mark Adams
GBGerome Breen
Gerome Breen
NCNa Cai
Na Cai
MHMatthew Hotopf
Matthew Hotopf
Background: This paper introduces the UK Biobank (UKB) second mental health questionnaire (MHQ2), describes its design, the respondents and some notable findings. UKB is a large cohort study with over 500,000 volunteer participants aged 40–69 years when recruited in 2006–2010. It is an important resource of extensive health, genetic and biomarker data. Enhancements to UKB enrich the data available. MHQ2 is an enhancement designed to enable and facilitate research with psychosocial and mental health aspects. Methods: UKB sent participants a link to MHQ2 by email in October-November 2022. The MHQ2 was designed by a multi-institutional consortium to build on MHQ1. It characterises lifetime depression further, adds data on panic disorder and eating disorders, repeats ‘current’ mental health measures and updates information about social circumstances. It includes established measures, such as the PHQ-9 for current depression and CIDI-SF for lifetime panic, as well as bespoke questions. Algorithms and R code were developed to facilitate analysis. Results: At the time of analysis, MHQ2 results were available for 169,253 UKB participants, of whom 111,275 had also completed the earlier MHQ1. Characteristics of respondents and the whole UKB cohort are compared. The major phenotypes are lifetime: depression (18%); panic disorder (4.0%); a specific eating disorder (2.8%); and bipolar affective disorder I (0.4%). All mental disorders are found less with older age and also seem to be related to selected social factors. In those participants who answered both MHQ1 (2016) and MHQ2 (2022), current mental health measure showed that fewer respondents have harmful alcohol use than in 2016 (relative risk 0.84), but current depression (RR 1.07) and anxiety (RR 0.98) have not fallen, as might have been expected given the relationship with age. We also compare lifetime concepts for test-retest reliability. Conclusions: There are some drawbacks to UKB due to its lack of population representativeness, but where the research question does not depend on this, it offers exceptional resources that any researcher can apply to access. This paper has just scratched the surface of the results from MHQ2 and how this can be combined with other tranches of UKB data, but we predict it will enable many future discoveries about mental health and health in general.

18 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XYXue Yang
Xue Yang
ZYZhaoyang Yin
Zhaoyang Yin
YCYue Cheng
Yue Cheng
WYWenfang Yang
Wenfang Yang
ZZZhonghai Zhu
Zhonghai Zhu
LZLingxia Zeng
Lingxia Zeng
The aim of this study was to assess the risk factors associated with the behavioral development among 24-month-old children in rural northwestern China. A total of 657 children whose mothers had participated in a double-blinded, randomized, controlled trial of antenatal micronutrient supplementation in western China were followed until 24 months of age. Their mental, psychomotor, and behavioral development were assessed by the Bayley Scales of Infant Development. Multivariate logistic regression models were used to examine the factors associated with infant behavioral development. Six behavioral factors of infants were presented: activity, social adaptability, reactivity, endurance, concentration, and motor coordination. Further analysis demonstrated that maternal malnutrition, exposure to risk factors during pregnancy, and adverse birth outcomes negatively affected the behavioral development of children at 24 months, which is a common co-occurrence with cognitive and emotional problems. These results suggest that strategies to improve infant behavioral development should consider the maternal pregnancy status.

14 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DLDanyang Li
Danyang Li
CLChris Wai Hang Lo
Chris Wai Hang Lo
CLCathryn Lewis
Cathryn Lewis
EVEvangelos Vassos
Evangelos Vassos
GBGerome Breen
Gerome Breen
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.